Phase 2 N=76 A Study in Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Phase 2: Progression-Free Survival Time — 4.7; 1.5 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary: Bayley III Gross Motor Scaled Score (Change From Baseline to 12 Month) — 4.8 units on a scale
Phase 2 N=36 Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Primary: Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) — -1.20; -0.94 units on a scale — p=0.07
Phase 2 N=10 Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Patients Who Achieve an Undetectable PSA (=< 0.2 ng/ml) — 0.0 percentage of patients
Phase 2 N=124 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Adult Nasal Type Extranodal NK/T-cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma
Primary: Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I) — 0 Participants
Phase 2 N=25 Postmenopausal Women Estrogen and Progesterone Infusion
Postmenopause · Aging
Primary: Effect of Aging on Estrogen Negative Feedback on LH — -52.8; -53.2 % change from baseline — p=0.90
Phase 2 N=42 Safety, Tolerability and Host Response to Lactobacillus Johnsonii
Healthy
Primary: Number of Participants Reporting Adverse Events — 1; 2 Participants
Phase 2 N=121 Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants
Ureaplasma Infections
Primary: Number of Participants With Survival And Transfer From NICU With Microbiological Eradication of Ureaplasma — 37; 55 Participants — p=<0.0001
Phase 2 N=20 Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer
Primary: Progression-free Survival. — 7.8 Months
Phase 2 N=30 Tau Imaging of Chronic Traumatic Encephalopathy
Chronic Traumatic Encephalopathy
Primary: Tau Protein Uptake.. — 1.1871; 1.1652; 1.5910 SUVr
Phase 2 N=41 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Adult Nasal Type Extranodal NK/T-cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma
Primary: Proportion of Confirmed Responses Defined to be a CR or PR Noted as the Objective Status — 0.21 proportion of CR or PR patients
Phase 2 N=15 Eplerenone for Central Serous Chorioretinopathy
Central Serous Chorioretinopathy
Primary: Complete Resolution of Subretinal Fluid — 0 participants
Phase 2 N=56 Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
Burkitt's Lymphoma · Burkitt'S-like Lymphoma
Primary: Complete Remission Rate: Percentage of Participants With Complete Remission (CR) — 85 percentage of participants
Phase 2 N=170 A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Neoplasms · Neoplasm Metastasis · Pancreatic Cancer
Primary: Phase 1b: Recommended Phase 2 Dose — 300 milligrams (mg)
Phase 2 N=243 PF-00489791 For The Treatment Of Raynaud's
Raynaud's Disease · Peripheral Vascular Disease
Primary: Change From Baseline in Mean Raynaud's Condition Score (RCS) at Week 4 — 3.04; 2.90; 2.98; 3.14 units on a scale — p=0.6513